QuickOpt Chronic Study

N/ACompletedNCT01172067

Abbott Medical Devices400 enrolled

Overview

The purpose of this study is to demonstrate that QuickOpt optimization can be as an alternative method for CRTP/D patients' optimization in clinical practice through the comparison of the improvement differences between the CRTP/D patients with different optimization at 12 months after implantation.The hypothesis is that the Heart Remolding parameter (LVESV) improvement of patients using QuickOpt parameters at 12 months after implant is not inferior (10%) to the patients by Echo optimization。

Clinical studies have demonstrated that the AVTI from QuickOptTM related significantly to the max aorta VTI (AVTI) by Echo, the concordance correlation coefficient (CCC) was so high from 0.96 to 0.99. But up to now, there are no clinical trials to evaluate mid-long term clinical outcome for CRTP/D patients by QuickOptTM and Echo optimization, this is indeed the main purpose of the study; in addition, the clinical impact, the status of arrhythmia and agents of all the enrolled patients, will be evaluated at 1 year after implant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

400

Conditions

Heart Failure

Interventions

Cardiac Resynchronization TherapyDEVICE

Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.

Optimization using echocardiographyDEVICE

Optimization of the AV/PV and VV delays using echocardiography

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * • Patient meets current CRT-P indications and be implanted with an SJM CRT-P device with V-V timing and a compatible lead system * Patient is able to provide written informed consent for study participation Exclusion Criteria: * • Patient has limited intrinsic atrial activity (≤ 40 bpm) * Patient has persistent or permanent AF * Patient has a 2o or 3o heart block * Patient's life expectancy is \<12 months * Patient is \<18 years old * Patient is pregnant * Patient is on IV inotropic agents * Patients who are ongoing other devices or agents study * Patients with heart transplanted or waiting for heart transplant * Patients with Hypertrophic and obstructive cardiomyopathy * Patients with severe aortic valve and mitral valve stenosis or regurgitation without replacement

Locations (1)

Fuwai Hospital

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Percent Change in Left Ventricular End Systolic Volume (LVESV) at 12 Months Compared to Baseline

The primary outcome is the percent change in LVESV at 12 months compared to baseline. This outcome measure is assessed through evaluation of echocardiograms at both baseline and 12 months, with a decrease in the percent change in LVESV at 12 months indicating clinical improvement. The percent change in patients with devices optimized with QuickOpt is compared with that of patients with devices optimized using standard echocardiography techniques to determine if one method of optimization results in a greater change in LVESV.

Time frame: Baseline and12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.